Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma

DSpace/Manakin Repository

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma

Citable link to this page

 

 
Title: Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
Author: Sonpavde, G; Choueiri, Toni K.

Note: Order does not necessarily reflect citation order of authors.

Citation: Sonpavde, G, and T K Choueiri. 2012. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. British Journal of Cancer 107(7): 1009-1016.
Full Text & Related Files:
Abstract: Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an option for highly selected patients and is associated with durable remissions in a small minority of patients. The toxicity profiles of specific agents and patient characteristics and comorbidities and costs have an important role in the current choice of therapy. Major challenges encountered in developing molecular biomarkers to guide therapy are tumour heterogeneity and standardisation of tissue collection and analysis. Although biomarkers are in their infancy of development, they should be a priority in early preclinical and clinical development in order to guide rational tailored development of emerging agents.
Published Version: doi:10.1038/bjc.2012.399
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461173/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10522883
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters